![David C. Brush](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David C. Brush
Corporate Officer/Principal presso Teva Spanish Holdco, Inc.
Profilo
David C.
Brush is currently the VP of Business Development & Strategic Planning at Teva Spanish Holdco, Inc. He previously held the same position at CPEX Pharmaceuticals, Inc., BTG International Ltd., and Morphochem, Inc. Brush received a graduate degree from Michigan State University and undergraduate and MBA degrees from the University of Michigan.
Posizioni attive di David C. Brush
Società | Posizione | Inizio |
---|---|---|
Teva Spanish Holdco, Inc.
![]() Teva Spanish Holdco, Inc. Pharmaceuticals: MajorHealth Technology Teva Spanish Holdco, Inc. manufactures, markets, and distributes pharmaceutical products. It specializes in offering treatment for cardiovascular, gastrointestinal, infectious, and neurological diseases. The firm was founded in 1974, and is headquartered in Exeter, NH. | Corporate Officer/Principal | 01/04/2007 |
Precedenti posizioni note di David C. Brush
Società | Posizione | Fine |
---|---|---|
BTG International Ltd.
![]() BTG International Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Boston Scientific Corp., BTG International Ltd. is a British company that engages in research and experimental development on natural sciences and engineering. The company is based in London, UK and was founded in 1991. | Corporate Officer/Principal | - |
CPEX Pharmaceuticals, Inc.
![]() CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Corporate Officer/Principal | - |
Morphochem, Inc.
![]() Morphochem, Inc. Pharmaceuticals: MajorHealth Technology Morphochem, Inc. manufactures and develops drugs. It uses proprietary whole-cell high throughput screening systems to discover novel compounds of therapeutic value for disorders including cancer & immunological, infectious & metabolic diseases, and for applications in agriculture. The company was founded by Prabhavathi Fernandes in 1997 and is located in Monmouth Junction, NJ | Corporate Officer/Principal | - |
Formazione di David C. Brush
University of Michigan | Masters Business Admin |
Michigan State University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Morphochem, Inc.
![]() Morphochem, Inc. Pharmaceuticals: MajorHealth Technology Morphochem, Inc. manufactures and develops drugs. It uses proprietary whole-cell high throughput screening systems to discover novel compounds of therapeutic value for disorders including cancer & immunological, infectious & metabolic diseases, and for applications in agriculture. The company was founded by Prabhavathi Fernandes in 1997 and is located in Monmouth Junction, NJ | Health Technology |
Teva Spanish Holdco, Inc.
![]() Teva Spanish Holdco, Inc. Pharmaceuticals: MajorHealth Technology Teva Spanish Holdco, Inc. manufactures, markets, and distributes pharmaceutical products. It specializes in offering treatment for cardiovascular, gastrointestinal, infectious, and neurological diseases. The firm was founded in 1974, and is headquartered in Exeter, NH. | Health Technology |
BTG International Ltd.
![]() BTG International Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Boston Scientific Corp., BTG International Ltd. is a British company that engages in research and experimental development on natural sciences and engineering. The company is based in London, UK and was founded in 1991. | Commercial Services |
CPEX Pharmaceuticals, Inc.
![]() CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Health Technology |
- Borsa valori
- Insiders
- David C. Brush